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Background: The aim of the present study was to analyse the incidence, risk ratio (RR) and prognoses of two types 
of medication-related osteonecrosis of the jaws (MRONJ): denosumab-related osteonecrosis of the jaws (DRONJ) 
and Bisphosphonate-Related Osteonecrosis of the Jaws (BRONJ) in cancer patients under treatment with deno-
sumab or zoledronic acid (ZA).
Material and Methods: An electronic and manual search was conducted for randomized controlled trials (RCTs) 
until May 2019. Assessment of the identified studies, risk of bias and data extraction were performed indepen-
dently by two reviewers. The incidence of DRONJ and BRONJ and the RR to develop MRONJ were calculated at 
1 year, 2 years and 3 years of exposure. It was also calculated the odds ratio (OR) of their respective prognoses. 
They were calculated normalizing the values of the individual studies to 1 year, 2 years or 3 years when necessary 
through robust regression models using a statistical program.
Results: From 1.277 references identified, 8 RCTs were included, which comprised a total of 13.857 patients with 
a variety of neoplasms. The incidence of DRONJ in cancer patients under treatment with denosumab ranged 
from 0.5 to 2.1% after 1 year, 1.1 to 3.0% after 2 years, and 1.3 to 3.2% after 3 years of exposure. The incidence 
of BRONJ in cancer patients under treatment with ZA ranged from 0.4 to 1.6% after 1 year of exposure, 0.8 to 
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Introduction
The increasing aging population goes hand in hand 
with a growing prevalence of disabling disease along 
with the use of medication to prevent and treat meta-
bolic bone diseases (1). The bone is the most common 
site for metastasis, mostly associated with malignant 
tumours of the breast (73%), prostate (68%) or lung 
(36%) (2). Bone metastases can cause skeletal-related 
events (SREs) such as pain, pathological fractures, hy-
percalcemia and spinal cord compression, requiring 
radiation and surgery. They are also linked to an over-
all increase in mortality.
In 2009, denosumab was approved by the Food and 
Drug Administration of the United States (FDA) and 
the European Medicines Agency (EMA) for the treat-
ment and prevention of bone metastases. Numerous 
case reports and case series have been published since 
then (3-6). In 2014, the American Association of Oral 
and Maxillofacial Surgeons (AAOMS) changed the 
term “Bisphosphonate-Related Osteonecrosis of the 
Jaws” (BRONJ) to “Medication-Related Osteonecro-
sis of the Jaws” (MRONJ) (7), as it is not only trig-
gered by bisphosphonates, but also by other antire-
sorptive and antiangiogenic drugs such as monoclonal 
antibodies (MABs), tyrosine kinase inhibitors (TKI), 
mammalian target of rapamycin inhibitors (mTORi), 
selective estrogen receptor modulators (SERMs) and 
immunosuppressants (8). MRONJ can be the cause of 
serious functional and masticatory disorders with an 
important influence on patient quality of life and may 
even result in death (9).
To date, the pathophysiology of MRONJ has not been 
fully elucidated. It is believed to be multifactorial, 
due to a decrease in physiological bone remodelling, 
inflammation, infection, inhibition of angiogenesis, 
and innate or acquired immunity dysfunction (10,11). 
However, there are two emerging theories on the aeti-
ology behind MRONJ. The first one, named “inside-
outside”, is based on the inhibition of osteoclastic ac-
tivity, resulting in a decrease of bone turnover. Due to 
this, jaw microdamage is not repaired and may lead to 
bone tissue necrosis and then to bone exposure over 
time. The second theory, termed “outside-inside”, is 
based on a local depression of the immune system, 
leading to local infection or inflammation inducing 
osteonecrosis (12).
The use of denosumab is expected to increase in the 
near future, because of its favourable profile in terms 
of avoiding adverse effects and renal toxicity com-
pared to zoledronic acid (ZA) in the treatment and 
prevention of SREs in patients with advanced solid 
tumours (13,14). Several meta-analyses have already 
reported the incidence of DRONJ (15,16). Neverthe-
less, several new randomized-controlled clinical trials 
have been published recently. Therefore, the aim of 
this updated systematic review and meta-analysis is to 
compare the incidence, risk ratio (RR) and prognoses 
of DRONJ and BRONJ in cancer patients under treat-
ment with denosumab and ZA.
Material and Methods
This review was focused on answering the following 
three PICO questions: “In cancer patients under treat-
ment with denosumab or ZA, do exist differences in 
the incidence of BRONJ (due to ZA) and DRONJ? If 
so, “what is the RR of MRONJ in patients treated with 
denosumab compared to patients treated with ZA?” and 
“do exist differences in the prognosis of BRONJ (due to 
ZA) compared to DRONJ?"
1) Study type: randomized clinical trials (RCTs).
2) Population: adult patients (> 18 years old) who were 
diagnosed with a solid tumour or with bone metastasis.
3) Intervention: subcutaneous denosumab in 120 mg 
doses every 4 weeks.
4) Comparison: intravenous ZA in 4 mg doses every 4 
weeks.
5) Outcome: the primary outcome was the incidence 
of denosumab and zoledronic acid-related MRONJ; the 
secondary outcome was the RR of DRONJ compared to 
ZA-related BRONJ; and the third outcome was the OR 
of their respective prognoses.
- Eligibility criteria
Only double-blinded, ZA-control randomized clinical trials 
(RCTs) including patients followed up for at least 8 months 
were selected. RCTs without ZA-control, and non-random-
ized controlled clinical trials, retrospective and prospective 
studies were excluded. All studies were limited to research 
in humans published in English, French and Spanish.
2.1% after 2 years, and 1.0 to 2.3% after 3 years of exposure. Statistically significant differences were found between 
denosumab and ZA in the risk of developing MRONJ after 1, 2 and 3 years of exposure. Nevertheless, there were no 
significant differences in terms of patient prognosis.
Conclusions: Denosumab is associated with a significantly higher risk of developing MRONJ compared to ZA. Nev-
ertheless, no differences were found in its prognoses.
Key words: Denosumab, zoledronic acid, bisphosphonate-associated osteonecrosis of the Jaws, medication-related 
osteonecrosis of the jaws, neoplasms.
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- Search strategy
An electronic search for articles published from 2003 
onwards was performed by entering the combination 
of the following search terms and Boolean operators: 
((Cancer [All Fields] OR Neoplasms [MeSH Terms]) 
AND (Denosumab [MeSH Terms]) AND (“Zoledronic 
Acid” [MeSH Terms]) AND (“Bisphosphonate-Asso-
ciated Osteonecrosis of the Jaw” [MeSH Terms] OR 
Osteonecrosis [MeSH Terms] OR MRONJ [All Fields] 
OR DRONJ [All Fields] OR ONJ [All Fields] OR 
ARONJ [All Fields])). An additional manual search 
was performed in selected journals of the field: “Jour-
nal of Dental Research”, “Oral Oncology”, “Clinical 
Oral Implant Research”, “International Journal of Oral 
Science”, “Oral Diseases”, “Journal of Oral Pathology 
& Medicine”, “International Journal of Oral and Max-
illofacial Surgery”, “Journal of Cranio-Maxillofacial 
Surgery”, “Journal of Oral and Maxillofacial Sur-
gery”, “Oral Surgery Oral Medicine Oral Pathology 
Oral Radiology”, “Medicina Oral Patología Oral y 
Cirugía Oral” and “International Journal of Clinical 
Oncology”.
- Information sources
The following five electronic databases were screened 
between January and May 2019: SCOPUS, MEDLINE 
(via OvidSP); Web of Science (WOS); the Central Reg-
istry of Controlled Clinical Trials of the Cochrane Li-
brary (CENTRAL), and the International Clinical Tri-
als Registry Platform of the World Health Organization 
(WHO ICTRP) (Fig. 1).
Fig. 1: PRISMA flow chart for the present systematic review and meta-analysis.
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RCT: Randomized Control Trial; NM: Not mentioned; I.V.: Intravenous Via.
Table 1: Characteristics of the included studies.
- Study selection & Data collection and items
Study selection and data extraction were performed 
independently by two reviewers (A.L. & P.M.M.). In 
the case of disagreement on inclusion or exclusion, a 
consensus was reached by discussion with a third re-
searcher (L.M.S.). The level of agreement between the 
reviewers was estimated using Cohen’s Kappa coef-
ficient at title/abstract selection and at full-text selec-
tion. A Kappa value of more than 0.80 was considered 
as substantial agreement between the reviewers. The 
following items were entered into a Microsoft Excel 
spreadsheet (version 15.17, Microsoft Inc. 2015) (Table 
1) (Table 2): 
name of the first author, year of publication; country 
of origin; type of study; study population; number of 
participants; age; gender; follow-up; number of cases of 
MRONJ; cases of resolved MRONJ; type of drug (de-
nosumab or ZA); dosage; frequency of administration, 
duration of drug administration, and route of adminis-
tration.
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- Statistical analysis
The incidence of MRONJ associated with denosumab 
and ZA was normalized when was necessary to 12, 
24 and 36 months through a regression model using 
the statistical program IBM SPSS Statistics 25.0. The 
function S(t): exp (b0 + (b1/t)) was selected since it has 
the best fit with the course of the disease according to 
the incidence of each study and their follow-ups. The 
incidence was calculated analysing the MRONJ events 
among all participants involved in the included studies 
with a confidence interval (CI) of 95% using fixed or 
random-effect models depending on the heterogeneity 
of the included trials. Cochran’s Q test and I2 were used 
to determine statistical heterogeneity (18). If the I2 value 
was between 0 and 50% and p-value of the Q test was 
> 0.05, the level of heterogeneity was interpreted to be 
within acceptable limits, and therefore, a fixed-effect 
model would be applied.
The RR of MRONJ and the OR of the respective prog-
noses was calculated by comparing denosumab vs. ZA 
with the same meta-analytic methodology as described 
above. The analyses and forest plots were performed us-
ing Comprehensive Meta-Analysis version 3 software 
(Biostat, Englewood, NJ, USA). The overall quality of 
evidence for outcomes addressed by direct evidence 
(analyses with RR or OR) was rated using the Grades 
of Recommendations, Assessment, Development and 
Evaluation (GRADE) approach grouped into very low, 
low, moderate or high (19).
- Risk of bias of included studies
The risk of bias for each study was determined using 
the Cochrane Collaboration Tool, described in the “Co-
chrane Handbook for Systematic Reviews of Interven-
tions” version 5.1.0 (20). The articles were assessed 
according to 7 domains: selection bias, allocation bias, 
blinding of participants and staff, blinding of the out-
come assessors, incomplete data, and selective notifica-
tion of results. Furthermore, one category was added: 
conflict of interest, as it may be an important factor to 
take into consideration for pharmaceutically related 
studies. Each category was graded as low risk with a 
point, represented by (+) in green, high risk with zero 
represented by (-) in red, and uncertain risk with half a 
point represented by (?) in yellow (Fig. 2) (21). Studies 
with 5 points or more have a lower risk of bias, whereas 
studies with less than five points exhibited a higher risk 
of bias (Table 3).
- Study quality
Publication bias was determined visually using funnel 
plots (22) using the statistical program Mix 2.0 (Fig. 2) (23).
Author Year Drugs Sample size
MRONJ Cases Associated Risk factors 
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Acid 945 5 (0.53%) 12 (1%)
NM - 12* 
(1,27%)* 10 (83%) 9 (75%) 1 (8%)










Acid 878 5 (0.6%) 8 (0.9%) 11 (1.3%) 7 (70%) 7 (64%) NM







NM - 18* 
(0,63%)*
NM - 31* 
(1,09%)* 37 (1.3%) NM
NM NM
Denosumab 2841 NM - 28* (0,98%)*
NM - 34* 
(1,55%)* 52 (1.8%) NM
Scaglio-





NM - 2* 
(0,38%)*
NM - 3* 
(0,84%)*
 3 (0.8%) - 
[21 months]
NM - 4* 
(1,05%)* NM
NM NM
Denosumab 406 NM - 1* (0,26%)*
NM - 3* 
(0,84%)*
3 (0.7%) - 
[21 months]






NM - 23* 
(2,67%)*
24 (3%) - 
[14,8 months]
NM - 27* 
(3,13%)*





Denosumab 850 NM - 33* (3,87%)*
35 (4%) - 
[15.8 months]
NM - 38* 
(4,46%)*




NM: Not mentioned; (*) normalized-value.
Table 2: The incidence rate and prognosis of MRONJ reported by the included studies in the quantitative analysis and its normalization to 1 
year, 2 years and 3 years of drug exposure.
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Fig. 2: Assessment of the risk of bias. A) The summary of the Cochrane Collaboration’s tool for assessing 
risk of bias for the included studies. B) Evaluation of publication bias through Funnel plot.
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Stopeck et al. 2010 1 5,5 0,5 1 1 1 1 1 0
Fizazi et al. 2011 1 6 1 1 1 1 1 1 0
Henry et al. 2011 1 6 1 1 1 1 1 1 0
Lipton et al. 2011 1 6 1 1 1 1 1 1 0
Scagliotti et al. 2012 1 5 0,5 1 1 0,5 1 1 0
Henry et al. 2014 1 6 1 1 1 1 1 1 0
Stopeck et al. 2015 1 5 0,5 1 1 0,5 1 1 0
Raje et al. 2018 1 6 1 1 1 1 1 1 0
TOTAL 5,62
Table 3: Tool for assessing risk of reporting biases.
Results
- Study selection
The electronic database search yielded 1.277 references 
(515 in MEDLINE, 534 in SCOPUS, 197 in WOS, 31 in 
CENTRAL and 0 in WHO ICTRP) and duplicates (n = 
87), triplicates (n = 49) and quadruplicates (n = 24) were 
removed. After screening by title and abstract, 32 papers 
were included for full-text assessment. No articles from 
the manual search were considered for inclusion. 20 arti-
cles did not comply with inclusion criteria due to a differ-
ent control group, and 4 articles did not provide sufficient 
information on MRONJ. Eight RCTs met our inclusion 
criteria (Fig. 1) (24-32). Nevertheless, two papers were 
excluded from the quantitative analysis for reporting 
on the same patient cohort (29,30,31). A Kappa value of 
0.874 was obtained for title/abstract selection, 0.841 for 
full-text selection and more than 0.90 for data extraction, 
indicating a high degree of inter-rater reliability.
- Characteristics of the studies
A summary of the general information of the includ-
ed studies is shown in Table 1. The dosage, frequency 
and route of administration of denosumab and ZA was 
concurrent for all included studies. As some studies 
presented different follow-up times, it was necessary 
to normalize the incidences to specific moments of the 
follow-up period. A 12, 24 and 36-month normalization 
was selected as intermediate follow-up times. Table 2 
shows a summary of MRONJ incidences reported by 
the studies and their normalizations when it was neces-
sary to apply.
- Risk of bias of included studies
The risk of bias for each study was determined using the 
Cochrane Collaboration Tool.
The studies showed an average risk of bias score of 5.62 
out of 7, indicating a low risk of bias (Fig. 2) (Table 3). 
However, all studies were funded by the pharmaceuti-
cal company that manufactures denosumab, which may 
result in some kind of bias.
- Publication bias
Funnel plot asymmetry should be used when there are 
at least 10 studies included in a meta-analysis. As seen 
in Fig. 2, there is moderate symmetry between studies. 
However, publication bias may not be detected since 
more studies are needed so that the power of evidence 
is strong enough to distinguish chance from real asym-
metry (22).
- Results of the effect
The quantitative analysis included 6 RCTs comprising a 
total of 13.857 patients, of whom 6.938 belonged to the 
denosumab group and 6.919 to the ZA group, allowing 
for analyses with great statistical power. The estimates 
of the individual studies were normalized to 12-, 24- 
and 36-months using a regression model according to 
MRONJ incidence rates and the follow-up periods re-
ported in the individual studies included. This allowed 
to draw a graph of the course of the disease that repre-
sents DRONJ and BRONJ incidences over time (Fig. 3).
When the pooled normalized incidence was calculated, 
statistical heterogeneity was detected for both groups. 
Therefore, a random-effects model was chosen. Never-
theless, a robust homogeneity was found when the RR 
or OR were calculated. A summary of the results of the 
meta-analysis is shown in Table 4. This analysis shows 
statistically significant differences between denosumab 
and ZA to develop MRONJ after 1 year (P = 0.030), 2 
years (P = 0.006) and 3 years of exposure (P = 0.007). 
Nevertheless, no differences were found between the 
prognosis of DRONJ cases compared to cases due to ZA 
(P = 0.163). The individual studies reported a favourable 
prognosis varying from 18% to 50% for cases due to 
denosumab and 8% to 43% for ZA-related cases, within 
their respective observation periods.
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BRONJ after 1 year 
with ZA
Q (df = 5) =   33.486 
p = 0.001
I^2 = 85.069 %
Random-
Effects
0.008 (0.004 - 
0.016)           p = 0.001   /
DRONJ after 1 year 
with DB
Q (df = 5) =   48.701
p = 0.001
I^2 = 89.733 %
Random-
Effects
0.010 (0.005 - 
0.021) p = 0.001
Comparison (mea-
sured with RR)       
Q (df = 5) =   1.029
p = 0.960
I^2 = 00.000 %
Fixed-Effects RR 1.448 (1.037 - 2.023)    p = 0.030
4 more 
per 1.000      
(1 - 9 more)
⊕⊕⊕∅ 
MODERATE  due 
to risk of biasa and 
imprecisionb 
BRONJ after 2 
years with ZA
Q (df = 5) =   22.891
p = 0.001
I^2 = 78.158 %
Random-
Effects
0.013 (0.008 - 
0.021) p = 0.001   
DRONJ after 2 
years with DB
Q (df = 5) =   34.630
p = 0.001
I^2 = 85.562 %
Random-
Effects
0.019 (0.011 - 
0.030) p = 0.001
Comparison (mea-
sured with RR)       
Q (df = 5) =   1.029
p = 0.960
I^2 = 00.000 %
Fixed-Effects RR 1.448 (1.114 - 1.881)           p = 0.006
4 more 
per 1.000      
(1 - 9 more)
⊕⊕⊕∅ 
MODERATE  due 
to risk of biasa and 
imprecisionb 
BRONJ after 3 
years with ZA
Q (df = 5) =   18.664
p = 0.002
I^2 = 73.210 %
Random-
Effects
 0.015 (0.010 - 
0.023)           p = 0.001   
DRONJ after 3 
years with DB
Q (df = 5) =   31.193
p = 0.001
I^2 = 83.971 %
Random-
Effects
0.021 (0.013 - 
0.032) p = 0.001
Comparison (mea-
sured with RR)     
Q (df = 5) =   1.626 
p = 0.898
I^2 = 00.000 %
Fixed-Effects RR 1.402  (1.095 - 1.795)    p = 0.007
3 more per 
1.000 (1 - 7 
more)
⊕⊕⊕∅ 
MODERATE  due 
to risk of biasa and 
imprecisionb 
MRONJ Prognosis Hererogeneity test Model Values (95% CI) p-Value
  Comparison (mea-
sured with OR)    
Q (df = 4) =   0.631
p = 0.889
I^2 = 00.000 %
Fixed-Effects OR 1.730 (0.801 - 3.739)           p = 0.163     -
⊕∅∅∅ VERY 
LOW  due to im-
precisionc
GRADE: Grading of Recommendations Assessment, Development and Evaluation; RR: Risk Ratio; OR: Odds Ratio; ZA: zoledronic acid; 
DB: denosumab; Downgraded initially from “high” to “moderate” due to: a) All included studies have been sponsored, supported or funded 
by Amgen, which may result in some kind of bias. b) The normalization of the different follow-up times provided approximated values. c) 
Insufficient information relative to prognosis.
Table 4: Meta-analysis results of the incidences and prognoses of MRONJ associated with zoledronic acid and Denosumab.
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Fig. 3: The summary of the normalized values of the individual studies and diagram of the course of MRONJ during the first 3 years.
Discussion
MRONJ is an uncommon but emerging complication 
of antiresorptive and antiangiogenic therapy. This up-
dated systematic review and meta-analysis, which to 
our knowledge, includes all published randomized-
controlled clinical trials to date comparing denosumab 
with ZA as control, aims to determine the incidence of 
MRONJ due to denosumab and ZA, the RR of develop-
ing MRONJ either due to denosumab or ZA, as well as 
the prognosis of DRONJ and ZA-related BRONJ.
This study has determined that the incidence of DRONJ 
in cancer patients under treatment with denosumab 
ranged from 0.5 to 2.1% (50 to 210 cases per 10.000 pa-
tients) after 1 year, 1.1 to 3.0% (110 to 300 cases per 
10.000 patients) after 2 years, and 1.3 to 3.2% (130 to 
320 cases per 10.000 patients) after 3 years of exposure. 
After longer periods of exposure, Stopeck et al. report-
ed DRONJ incidences of 6.9% (30,31). In this sense, as 
it can be seen in Fig. 3, the MRONJ incidence is expect-
ed to increase over the exposure time. The incidence 
of BRONJ in cancer patients under treatment with ZA 
ranged from 0.4 to 1.6% (40 to 160 cases per 10.000 
patients) after 1 year, 0.8 to 2.1% (80 to 210 cases per 
10.000 patients) after 2 years, and 1.0 to 2.3% (100 to 
230 cases per 10.000 patients) after 3 years of exposure. 
Some authors, such as Ruggiero et al. reported that in 
cancer patients under treatment with ZA, the risk of de-
veloping BRONJ reaches 1% (100 cases per 10.000 pa-
tients) and in patients under treatment with denosumab 
the risk of developing DRONJ ranges from 0.7 to 1.9% 
(70 to 190 cases per 10.000 patients) (7). Others, in con-
trast to these results, have reported a higher MRONJ 
incidence linked to denosumab (10 %, P = 0.21) with 
a median follow-up time of 22.0 months, and also due 
to bisphosphonates (6.7%, P = 0.21) (33). This higher 
incidence could be associated with the fact that the 
study of Loyson et al. is specifically aimed at evaluating 
MRONJ cases, contrary to the studies included in this 
review that have other priority objectives.
Many clinicians switch therapy from bisphosphonates 
to denosumab for their patients due to its multiple ad-
vantages, such as superior prevention of SREs, subcu-
taneous administration instead of intravenous admin-
istration, and no dosage adjustment in case of renal 
insufficiency (33). Loyson et al. reported that the switch 
from bisphosphonates to denosumab can be considered 
as safe as having an equivalent exposure to denosumab 
from the start (33).
According to the results of this analysis, the use of de-
nosumab is associated with a significantly higher risk 
of developing MRONJ compared to ZA at 1 year (RR 
1.448 CI: 1.037-2.023), 2 years (RR 1.488 CI: 1.114-
1.881) and 3 years of treatment (RR 1.402 CI: 1.095-
1.795). Thus, clinicians should be aware of this risk, 
promoting preventive measures such as comprehensive 
oral examinations with appropriate radiographs, oral 
hygiene instructions, maintenance of good oral health, 
completion of necessary dental treatments before initi-
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ating antiresorptive therapy etc. (34). Similarly, Owo-
sho et al. reported that denosumab was associated with 
an earlier occurrence of MRONJ compared to ZA and 
pamidronate (35). Stavropoulos et al. consider that in 
patients under high doses of antiresorptive therapy, im-
plant placement, explantation or their presence per se 
may trigger MRONJ (36). Most authors reported that 
MRONJ was strongly linked to dental extractions (45%) 
or poor oral hygiene (between 54 and 93%), simulta-
neous chemotherapy (between 60 and 75%), or the use 
of removable dentures with mucosal support (23,25,29-
31). All of the causes mentioned above result in bacteria 
being in contact with susceptible bone or also in a de-
crease of the immune system in its role of protecting the 
oral mucosa from a bacterial-contaminated ecosystem.
No statistically significant differences were found in the 
prognosis of MRONJ cases due to denosumab or ZA 
(P = 0.163). However, individual studies reported that 
DRONJ cases have a slightly higher tendency to resolve, 
ranging from 18 to 50% compared to ZA, which ranges 
from 8% to 43%. This might be related to the revers-
ibility mechanism inherent to denosumab, which is not 
found in bisphosphonates in general.
This systematic review and meta-analysis present cer-
tain limitations, such as the inclusion of different types 
of tumours, subcutaneously administered denosumab 
against intravenous ZA, the normalization of the differ-
ent follow-up times providing approximated values or 
that all included randomized trials received some kind 
of funding by the pharmaceutical company that manu-
factures denosumab. On the other hand, the strengths 
of this study lie in the strict inclusion criteria used for 
homogeneous study selection, in the level of evidence 
provided by the selected RCTs, the low risk of bias of 
the individual studies, and in the sample sizes that allow 
for analyses with great statistical power.
Future RCTs should be carried out in more detail, mea-
suring the real incidence per year, as well as the years 
after the exposure to medication for more clarity. Speci-
fying further details could be of great value, such as 
whether oral examinations were carried out at enrol-
ment or periodically, the intake of other concomitant 
drugs, the stage of MRONJ cases, and the number of 
patients undergoing dental surgical procedures along 
with the reason for surgery.
Conclusions
Based on the findings of the present study, the use of de-
nosumab is associated with a significantly higher risk of 
developing MRONJ compared to ZA. Thus, clinicians 
should be aware of this risk, and adapt or plan for pre-
ventive measures such as thorough dental examinations 
and interventions prior to the initiation of medication, 
as well as oral health maintenance and avoidance of sur-
gical procedures during active therapy.
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